- Home
- AKBA vs ALM Comparison
AKBA vs ALM Comparison
Compare AKBA & ALM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ALM
- Stock Information
- Founded
- AKBA 2007
- ALM N/A
- Country
- AKBA United States
- ALM Canada
- Employees
- AKBA N/A
- ALM N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ALM Other Metals and Minerals
- Sector
- AKBA Health Care
- ALM Basic Materials
- Exchange
- AKBA Nasdaq
- ALM Nasdaq
- Market Cap
- AKBA 861.7M
- ALM 958.4M
- IPO Year
- AKBA 2014
- ALM N/A
- Fundamental
- Price
- AKBA $3.04
- ALM $4.05
- Analyst Decision
- AKBA Strong Buy
- ALM Strong Buy
- Analyst Count
- AKBA 5
- ALM 2
- Target Price
- AKBA $6.90
- ALM $7.00
- AVG Volume (30 Days)
- AKBA 4.0M
- ALM 1.0M
- Earning Date
- AKBA 08-07-2025
- ALM 08-14-2025
- Dividend Yield
- AKBA N/A
- ALM N/A
- EPS Growth
- AKBA N/A
- ALM N/A
- EPS
- AKBA N/A
- ALM N/A
- Revenue
- AKBA $203,733,000.00
- ALM $20,657,545.00
- Revenue This Year
- AKBA $27.95
- ALM $167.51
- Revenue Next Year
- AKBA $43.88
- ALM $107.39
- P/E Ratio
- AKBA N/A
- ALM N/A
- Revenue Growth
- AKBA 16.75
- ALM 9.87
- 52 Week Low
- AKBA $1.24
- ALM $3.16
- 52 Week High
- AKBA $4.08
- ALM $5.50
- Technical
- Relative Strength Index (RSI)
- AKBA 34.84
- ALM N/A
- Support Level
- AKBA $2.92
- ALM N/A
- Resistance Level
- AKBA $3.44
- ALM N/A
- Average True Range (ATR)
- AKBA 0.15
- ALM 0.00
- MACD
- AKBA -0.06
- ALM 0.00
- Stochastic Oscillator
- AKBA 13.79
- ALM 0.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ALM Almonty Industries Inc. Common Shares
Almonty Industries Inc is engaged in the mining, processing, and shipping of tungsten concentrate from its Los Santos tungsten mine located near Salamanca, Spain - the Los Santos Mine, the processing and shipping of tungsten concentrate from its Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal - the Panasqueira Mine, the evaluation of its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora - the Valtreixal Mine, as well as the exploration and evaluation of its Sangdong tungsten mine project located in Gangwon Province, Republic of Korea - the Sangdong Mine.